Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio Reports Q1 2025 Financial Results
- Cautious Hold Rating for Zura Bio Amid Financial Challenges and Clinical Uncertainties
- Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
- Zura Bio price target lowered to $19 from $20 at Oppenheimer
- Zura Bio Limited: 2024 Financial Results and Strategic Progress